Skip to Content

Press Releases

Press Releases

Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
Jun 17, 2022
Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient
Jun 09, 2022
Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient
Jun 09, 2022
Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient
Jun 09, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
Jun 09, 2022
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
Jun 08, 2022
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs
Jun 06, 2022
Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting
Jun 01, 2022
Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance
May 24, 2022
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
Apr 26, 2022
Displaying 11 - 20 of 406